Polyarteritis Nodosa disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PAN MCID: PLY017 MIFTS: 62	Polyarteritis Nodosa (PAN) Categories: Bone diseases, Cardiovascular diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Polyarteritis Nodosa

MalaCards integrated aliases for Polyarteritis Nodosa:

Name: Polyarteritis Nodosa ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ⁴³ ¹⁴ ¹⁶ ⁷¹ ³¹ ³³

Periarteritis Nodosa ⁵⁸ ⁷⁵ ³³

Polyarteritis ¹⁹ ⁷⁵ ⁷¹

Periarteritis ¹⁹ ⁷¹

Pan ¹⁹ ⁵⁸

Pan - [polyarteritis Nodosa] ³³

Kussmaul-Maier Disease ⁵⁸

Panarteritis Nodosa ³³

Kussmaul Disease ³³

Arteritis Nodosa ³³

Polyangiitis ³³

Panangiitis ³³

Characteristics:

Prevelance:

1-9/100000 (Sweden, France, Norway, Europe) 1-9/1000000 (Australia, Spain) <1/1000000 (Germany) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Immune diseases Neuronal diseases Cardiovascular diseases Nephrological diseases Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the musculoskeletal system and connective tissue

Systemic connective tissue disorders

Polyarteritis nodosa and related conditions

Polyarteritis nodosa

Polyarteritis with lung involvement [Churg-Strauss]

ICD11: ³³

Diseases of the immune system

Nonorgan specific systemic autoimmune disorders

Vasculitis

Polyarteritis nodosa

Orphanet: ⁵⁸

Rare neurological diseases

Rare circulatory system diseases

Rare renal diseases

Rare systemic and rhumatological diseases

External Ids:

Sources

Summaries for Polyarteritis Nodosa

GARD: ¹⁹ Polyarteritis nodosa (PAN) is a blood vessel disease characterized by inflammation of small and medium-sized arteries (vasculitis), preventing them from bringing oxygen and food to organs. Most cases occur in the 4th or 5th decade of life, although it can occur at any age. PAN most commonly affects vessels related to the skin, joints, peripheral nerves, gastrointestinal tract, heart, eyes, and kidneys. Symptoms are caused by damage to affected organs and may include fever, fatigue, weakness, loss of appetite, weight loss, muscle and joint aches, rashes, numbness, and abdominal pain. The underlying cause of PAN is unknown.

MalaCards based summary: Polyarteritis Nodosa, also known as periarteritis nodosa, is related to mononeuritis multiplex and familial mediterranean fever. An important gene associated with Polyarteritis Nodosa is ADA2 (Adenosine Deaminase 2), and among its related pathways/superpathways are Integrin Pathway and Cytokine Signaling in Immune system. The drugs Alemtuzumab and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and neutrophil, and related phenotypes are fever and arthralgia

Orphanet: ⁵⁸ A rare, clinically heterogeneous, systemic disease characterized by necrotizing inflammatory lesions affecting medium-sized blood vessels. It most commonly affects skin, joints, peripheral nerves and the gastrointestinal tract.

Disease Ontology: ¹¹ A vasculitis that is characterized by necrotizing inflammation of medium or small arteries.

Wikipedia: ⁷⁵ Polyarteritis nodosa (PAN) is a systemic necrotizing inflammation of blood vessels (vasculitis)... more...

Sources

Related Diseases for Polyarteritis Nodosa

Diseases in the Polyarteritis Nodosa family:

Systemic Polyarteritis Nodosa	Secondary Polyarteritis Nodosa
Primary Polyarteritis Nodosa

Diseases related to Polyarteritis Nodosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1244)

#	Related Disease	Score	Top Affiliating Genes
1	mononeuritis multiplex	31.6	PRTN3 MPO HLA-DRB1 CRP APOH ADA2
2	familial mediterranean fever	31.4	MEFV IL6 CRP
3	churg-strauss syndrome	31.3	PRTN3 MPO HLA-DRB1
4	microscopic polyangiitis	31.3	PRTN3 MPO HLA-DRB1 ADA2
5	acute kidney failure	31.3	PRTN3 IL6 GPT
6	hepatitis b	31.2	IL6 IFNA2 HLA-DRB1 GPT
7	purpura	31.1	SELP IL6 HLA-DRB1 CRP APOH
8	orchitis	31.1	IL6 IFNA2 CRP
9	viral infectious disease	31.1	IL6 IFNA2 ICAM1 GPT
10	intestinal perforation	31.0	IL6 GPT CRP
11	cryoglobulinemia	31.0	IL6 IFNA2 HLA-DRB1 GPT
12	spondyloarthropathy 1	31.0	PRTN3 IL6 CRP
13	thrombocytosis	31.0	SELP IL6 CRP
14	kawasaki disease	31.0	VCAM1 SELP SELL SELE GPT CRP
15	raynaud disease	30.9	SELE CRP APOH
16	systemic scleroderma	30.9	PRTN3 IL6 HLA-DRB1 CRP
17	granulomatous angiitis	30.9	PRTN3 CRP
18	anterior uveitis	30.9	IL6 HLA-DRB1 CRP
19	collagen disease	30.9	PRTN3 IL6 CRP APOH
20	testicular infarct	30.8	CRP ADA2
21	systemic onset juvenile idiopathic arthritis	30.8	IL6 HLA-DRB1
22	hepatic infarction	30.8	GPT APOH
23	antiphospholipid syndrome	30.8	VCAM1 SELP SELE CRP APOH
24	exanthem	30.8	PRTN3 MPO IL6 GPT CRP
25	cardiac tamponade	30.8	IL6 GPT CRP
26	disseminated intravascular coagulation	30.8	IL6 GPT CRP
27	livedoid vasculitis	30.8	PRTN3 APOH ADA2
28	hepatitis a	30.7	IFNA2 HLA-DRB1 GPT
29	pyelonephritis	30.7	IL6 GPT CRP
30	serum amyloid a amyloidosis	30.7	MEFV IL6 CRP
31	thrombophlebitis	30.7	SELP CRP APOH
32	uveitis	30.7	IL6 IFNA2 ICAM1 HLA-DRB1
33	crescentic glomerulonephritis	30.7	PRTN3 MPO CRP
34	erythema nodosum	30.7	VCAM1 SELE IL6 ICAM1 CRP
35	adult-onset still's disease	30.7	MEFV IL6 CRP
36	retinal artery occlusion	30.7	IL6 ICAM1 CRP APOH
37	limb ischemia	30.7	PECAM1 IL6 CRP
38	pericarditis	30.7	MEFV IL6 CRP
39	pericardial effusion	30.7	IL6 GPT CRP
40	brucellosis	30.7	SELL MPO MEFV IL6 CRP
41	rheumatic fever	30.6	IL6 ICAM1 HLA-DRB1
42	acalculous cholecystitis	30.6	GPT CRP
43	juvenile rheumatoid arthritis	30.6	IL6 HLA-DRB1 CRP
44	pulmonary tuberculosis	30.6	IL6 HLA-DRB1 CRP
45	psoriatic arthritis	30.6	SELE IL6 HLA-DRB1 CRP
46	facial paralysis	30.6	PRTN3 IL6 CRP
47	buerger disease	30.6	VCAM1 ICAM1 CRP APOH
48	kidney disease	30.6	VCAM1 SELE PRTN3 MEFV IL6 ICAM1
49	thrombotic thrombocytopenic purpura	30.6	SELP SELE APOH
50	mononeuropathy	30.6	PRTN3 MPO IL6 CRP

Graphical network of the top 20 diseases related to Polyarteritis Nodosa:

Sources

Symptoms & Phenotypes for Polyarteritis Nodosa

Human phenotypes related to Polyarteritis Nodosa:

⁵⁸ ³⁰ (show all 28)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001945
2	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
3	myalgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0003326
4	abnormality of the kidney ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000077
5	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001824
6	polyneuritis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0031003
7	elevated circulating c-reactive protein concentration ³⁰	Frequent (33%)		HP:0011227
8	hypertension ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000822
9	skin ulcer ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200042
10	subcutaneous nodule ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001482
11	abdominal pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002027
12	pericarditis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001701
13	erythema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010783
14	abnormality of the gastrointestinal tract ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011024
15	cutis marmorata ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000965
16	raynaud phenomenon ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030880
17	sensory axonal neuropathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003390
18	morphological central nervous system abnormality ³⁰	Occasional (7.5%)		HP:0002011
19	abnormality of the eye ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000478
20	cardiomyopathy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001638
21	pleuritis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002102
22	peripheral neuropathy ⁵⁸		Frequent (79-30%)
23	abnormal lung morphology ⁵⁸		Occasional (29-5%)
24	abnormality of the nervous system ⁵⁸		Occasional (29-5%)
25	abnormality of cardiovascular system morphology ⁵⁸		Occasional (29-5%)
26	morphological abnormality of the central nervous system ⁵⁸		Occasional (29-5%)
27	elevated c-reactive protein level ⁵⁸		Frequent (79-30%)
28	abnormality of skin morphology ⁵⁸		Very frequent (99-80%)

MGI Mouse Phenotypes related to Polyarteritis Nodosa:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.21	APOH CRP ICAM1 IL6 ITGAL ITGB2
2	cellular	MP:0005384	10.1	ICAM1 IL6 ITGAL ITGB2 MEFV MSN
3	immune system	MP:0005387	10.06	CRP ICAM1 ICAM2 IFNA2 IL6 ITGAL
4	cardiovascular system	MP:0005385	10	CRP ICAM1 IL6 ITGB2 MPO MSN
5	respiratory system	MP:0005388	9.56	ICAM2 IFNA2 IL6 MSN PECAM1 SELE
6	hematopoietic system	MP:0005397	9.5	ICAM1 ICAM2 IFNA2 IL6 ITGAL ITGB2

Sources

Drugs & Therapeutics for Polyarteritis Nodosa

Drugs for Polyarteritis Nodosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Alemtuzumab

Approved, Investigational

Phase 4

216503-57-0

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Povidone K30

Approved, Experimental, Withdrawn

Phase 4

9003-39-8

6917 131751496

Hydroxychloroquine

Approved

Phase 4

118-42-3

3652

Tofacitinib

Approved, Investigational

Phase 4

477600-75-2

9926791

Rituximab

Approved

Phase 4

174722-31-7

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Dermatologic Agents

Phase 4

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Protein Kinase Inhibitors

Phase 4

Tin Fluorides

Phase 4

Antirheumatic Agents

Phase 4

Antineoplastic Agents, Immunological

Phase 4

Immunologic Factors

Phase 4

Alendronic acid

Approved

Phase 3

121268-17-5, 66376-36-1

2088

Etanercept

Approved, Investigational

Phase 2, Phase 3

185243-69-0

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Benralizumab

Approved, Investigational

Phase 3

1044511-01-4

Azathioprine

Approved

Phase 3

446-86-6

2265

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Mycophenolic acid

Approved, Investigational

Phase 3

24280-93-1

446541

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 3

67-97-0, 1406-16-2

5280795 10883523

Alfacalcidol

Approved, Nutraceutical

Phase 3

41294-56-8

5282181

Dexchlorpheniramine

Experimental, Investigational

Phase 3

25523-97-1

33036

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Gusperimus

Investigational

Phase 3

89149-10-0, 98629-43-7

55362

Vitamins

Phase 3

Trace Elements

Phase 3

Calciferol

Phase 3

Micronutrients

Phase 3

Plasma Substitutes

Phase 3

Analgesics

Phase 2, Phase 3

Analgesics, Non-Narcotic

Phase 2, Phase 3

Hydroxycholecalciferols

Phase 3

Anti-Inflammatory Agents, Non-Steroidal

Phase 2, Phase 3

Pharmaceutical Solutions

Phase 3

Anti-Asthmatic Agents

Phase 3

Respiratory System Agents

Phase 3

Gastrointestinal Agents

Phase 2, Phase 3

Antimetabolites

Phase 3

Interventional clinical trials:

(show top 50) (show all 104)

#	Name	Status	NCT ID	Phase	Drugs
1	CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients	Unknown status	NCT00400075	Phase 4	azathioprine;cyclophosphamide
2	Alemtuzumab for ANCA Associated Refractory Vasculitis - a Study of Safety and Efficacy	Unknown status	NCT01405807	Phase 4	Alemtuzumab
3	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants	Completed	NCT00307671	Phase 4	prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
4	Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis	Completed	NCT02169219	Phase 4	Glucocorticoids;Rituximab
5	A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis	Completed	NCT02115997	Phase 4	Methylprednisolone;Prednisone;Rituximab
6	Hydroxychloroquine in ANCA Vasculitis Evaluation - A Multicentre, Randomised, Double-blind, Placebo-controlled Trial	Recruiting	NCT04316494	Phase 4	Hydroxychloroquine;Placebo
7	MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial	Recruiting	NCT03164473	Phase 4	Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
8	Randomized Trial of Tofacitinib Versus Methotrexate for Maintenance Therapy in Granulomatosis With Polyangiitis	Recruiting	NCT04944524	Phase 4	Tofacitinib;Methotrexate
9	Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial	Active, not recruiting	NCT02198248	Phase 4	Rituximab;Glucocorticoids
10	Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis	Terminated	NCT02626845	Phase 4	Rituximab
11	Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD")	Terminated	NCT00747461	Phase 4
12	Comparative Study of the Efficacy of Induction Therapy With Cyclophosphamide or Mycophenolate Mofetil for Non-Life-Threatening Relapses of PR3- or MPO-ANCA Associated Vasculitis	Unknown status	NCT00103792	Phase 3	mycophenolate mofetil;cyclophosphamide
13	Treatment of ANCA-Associated Vasculitides : Corticosteroids and Pulse Cyclophosphamide Followed by Maintenance Therapy With Methotrexate or Azathioprine: a Prospective Multicenter Randomized Trial	Unknown status	NCT00349674	Phase 3	Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
14	Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors	Completed	NCT00647166	Phase 3	corticosteroid and azathioprine;corticosteroid and placebo
15	Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomized Controlled Trial	Completed	NCT00987389	Phase 3	Glucocorticoids [Standard Dose];Glucocorticoids [Reduced Dose]
16	MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II	Completed	NCT01731561	Phase 3	Rituximab (Arm B);Rituximab (Arm A)
17	MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis	Completed	NCT00748644	Phase 3	Rituximab;Azathioprine
18	Randomized Trial of Intravenous Pulse Versus Oral Continuous Cyclophosphamide for Induction of Remission in Systemic ANCA-Associated Vasculitides	Completed	NCT00430105	Phase 2, Phase 3	cyclophosphamide
19	An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis	Completed	NCT01697267	Phase 3	Azathioprine
20	Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)	Completed	NCT00104299	Phase 2, Phase 3	Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
21	A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy	Completed	NCT02020889	Phase 3	Placebo
22	Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study	Completed	NCT02807103	Phase 3	Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
23	A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis	Completed	NCT01663623	Phase 3	Azathioprine
24	Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol.	Completed	NCT00138983	Phase 3	Alendronate versus alfacalcidol (1-alpha OH vitamin D)
25	Wegener's Granulomatosis Etanercept Trial (WGET)	Completed	NCT00005007	Phase 2, Phase 3	Etanercept
26	Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)	Recruiting	NCT02108860	Phase 3	Abatacept;placebo
27	A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy	Recruiting	NCT05263934	Phase 3	Placebo matching mepolizumab;Placebo matching depemokimab
28	Evaluation of MEpolizumab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study	Recruiting	NCT05030155	Phase 3	Mepolizumab;cyclophosphamide/azathioprine;Placebo
29	The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach	Recruiting	NCT01940094	Phase 3	5 mg Prednisone;0 mg Prednisone
30	Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis	Active, not recruiting	NCT03920722	Phase 3	Rituximab;placebo
31	A Randomized, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy	Active, not recruiting	NCT04157348	Phase 3
32	Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)	Active, not recruiting	NCT03298061	Phase 3	Mepolizumab;Prednisolone
33	The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach	Active, not recruiting	NCT01933724	Phase 3	5 mg prednisone;0 mg prednisone
34	Randomised, Evaluator-Blinded, Multicentre, International, Parallel-Group, Active-Controlled Clinical Trial of Gusperimus Versus Conventional Therapy in Relapse of Granulomatosis With Polyangiitis (Wegener's Granulomatosis) SPARROW Study - SPAnidin in Relapsing GRanulomatosis With POlyangiitis Wegener's Granulomatosis)	Terminated	NCT01446211	Phase 3	Gusperimus + glucocorticoids;cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
35	Randomised Trial of Plasma Exchange or High Dose Methyl Prednisolone as Adjunctive Therapy for Severe Renal Vasculitis	Terminated	NCT01408836	Phase 2, Phase 3	Intravenous methyl prednisolone;Methyl prednisolone
36	Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener's Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial	Terminated	NCT00307658	Phase 3	Intravenous immunoglobulins (human immunoglobulins G)
37	Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis	Terminated	NCT00307645	Phase 3	Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
38	Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.	Unknown status	NCT00751517	Phase 2	Methotrexate;Cyclophosphamide
39	Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study	Unknown status	NCT02947945	Phase 2	Reslizumab
40	Lamivudine for Chronic Hepatitis B	Completed	NCT00001457	Phase 2	Lamivudine
41	A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)	Completed	NCT03895801	Phase 2	IFX-1;Placebo-IFX-1;Glucocorticoid (GC);Placebo-Glucocorticoid (Placebo-GC)
42	A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis	Completed	NCT01750697	Phase 2	Rituximab
43	Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis	Completed	NCT00753103	Phase 2	Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
44	Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach	Completed	NCT01988506	Phase 2	Interleukin 2
45	Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis	Completed	NCT00530075	Phase 2	Gusperimus
46	A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis	Completed	NCT00468208	Phase 1, Phase 2	Abatacept
47	An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis	Completed	NCT00001256	Phase 2	prednisone and methotrexate
48	A Randomized Trial Examining the Use of Daclizumab in Wegener's Granulomatosis	Completed	NCT00040248	Phase 2	Daclizumab
49	Treatment of Wegener's Granulomatosis With Cyclophosphamide	Completed	NCT00001155	Phase 2	cyclophosphamide
50	A Randomized Trial Comparing Methotrexate Versus Mycophenolate Mofetil for Remission Maintenance in Wegener's Granulomatosis and Related Vasculitides	Completed	NCT00004567	Phase 2	Mycophenolate Mofetil

Search NIH Clinical Center for Polyarteritis Nodosa

Cochrane evidence based reviews: polyarteritis nodosa

Sources

Genetic Tests for Polyarteritis Nodosa

Genetic tests related to Polyarteritis Nodosa:

#	Genetic test	Affiliating Genes
1	Polyarteritis Nodosa ²⁸

Sources

Anatomical Context for Polyarteritis Nodosa

Organs/tissues related to Polyarteritis Nodosa:

MalaCards : Lung, Skin, Neutrophil, Heart, Bone, Kidney, T Cells

Sources

Publications for Polyarteritis Nodosa

Articles related to Polyarteritis Nodosa:

(show top 50) (show all 9820)

#	Title	Authors	PMID	Year
1	Mutations/polymorphisms in a monogenetic autoinflammatory disease may be susceptibility markers for certain rheumatic diseases: lessons from the bedside for the benchside. ⁵³ ⁶²	Ozen S	19796529	2009
2	Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. ⁵³ ⁶²	Yalcinkaya F...Ozen S	18035151	2007
3	Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? ⁵³ ⁶²	Meyer MF...Schatz H	11149660	2000
4	Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. ⁵³ ⁶²	Tekin M...Cakar N	10709887	2000
5	[A reversible posterior leukoencephalopathy syndrome in a patient with classical polyarteritis nodosa]. ⁵³ ⁶²	Arai M...Wada M	9146079	1997
6	Anti-neutrophil cytoplasmic antibody for proteinase 3 in a child with polyarteritis nodosa. ⁵³ ⁶²	Ito Y...Kato H	7754755	1995
7	[Autoantibodies associated with vasculitis]. ⁵³ ⁶²	Aotsuka S	7933581	1994
8	Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. ⁵³ ⁶²	Guillevin L...Trepo C	7912504	1994
9	Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. ⁵³ ⁶²	Henshaw TJ...Williams RC	7907475	1994
10	Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. ⁵³ ⁶²	Kallenberg CG...Tervaert JW	1466365	1992
11	[Antineutrophil cytoplasmic antibodies--ANCA]. ⁵³ ⁶²	Vencovsky J...Becvar R	1464072	1992
12	Myocardial Involvement in Systemic Autoimmune Rheumatic Diseases. ⁶²	Zagouras AA...Tang WHW	36424026	2023
13	A "Leopard Man" Aspect on 18 F-FDG PET/CT Revealing a VEXAS Syndrome. ⁶²	Fagart A...Rousselin C	36252945	2023
14	Structured histopathology and laboratory evidence in nasal polyposis with different pathogenesis. ⁶²	Brescia G...Marioni G	36257231	2023
15	Immunoadsorption and plasmapheresis at the ICU - A description of the frequencies and indications in a single center experience and a case report. ⁶²	Koball S...Mitzner S	36468348	2022
16	Antineutrophil Cytoplasm Antibody-Associated Vasculitides Valvular Impairment: Multicenter Retrospective Study and Systematic Review of the Literature. ⁶²	Jeantin L...French Vasculitis Study Group	35840158	2022
17	Granulomatosis with polyangiitis: Common and uncommon presentations. ⁶²	Tee QX...Lau KK	36125112	2022
18	New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors. ⁶²	Holubar J...Goulabchand R	36125736	2022
19	Localised presentation of granulomatosis with polyangiitis: The great masquerade. ⁶²	Das S...Rakesh UK	35907569	2022
20	Epidemiology of granulomatosis with polyangiitis and microscopic polyangiitis in adults in France. ⁶²	Bataille PM...Terrier B	36108505	2022
21	Adult case of chronic granulomatous disease mimicking granulomatosis with polyangiitis. ⁶²	Zengin Acemoglu SS...Sat B	36455104	2022
22	Eosinophilic granulomatosis with polyangiitis. ⁶²	Villa-Forte A	36259957	2022
23	Eosinophilic Granulomatosis With Polyangiitis With a Pathologically Proven Calcified Lung Nodule. ⁶²	Tada N...Shiozawa E	36455937	2022
24	[18F]FDG PET/CT guided biopsy confirms diagnosis of granulomatosis with polyangiitis. ⁶²	Krebold AK...Dierks A	35977670	2022
25	Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. ⁶²	Bettiol A...European EGPA Study Group	35850947	2022
26	Missing Orbital Bones in a Patient with Granulomatosis with Polyangiitis. ⁶²	Nakajima I...Yamashiro K	35773074	2022
27	Extravascular Necrotizing Granuloma: A Diagnostic Clue for Eosinophilic Granulomatosis With Polyangiitis. ⁶²	Tanomogi N...Kato M	35705238	2022
28	Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation. ⁶²	Gibson LE	35599359	2022
29	Uncommon onset manifestations without renal involvement in microscopic polyangiitis: A case report. ⁶²	Calinoiu AL...Minca DG	36420356	2022
30	Clinical patterns and risk factors in scleritis: a multicentric study in Colombia. ⁶²	de-la-Torre A...Rojas-Carabali W	35796822	2022
31	[Renal manifestations in vasculitides of small and medium-sized vessels]. ⁶²	Schneider J...Venhoff N	36331616	2022
32	Updates of ocular involvement in granulomatosis with polyangiitis. ⁶²	Mei L...Yan H	36473987	2022
33	Retrospective assessment of porcine circovirus 3 (PCV-3) in formalin-fixed, paraffin-embedded tissues from pigs affected by different clinical-pathological conditions. ⁶²	Cobos A...Segales J	36471405	2022
34	Images in Vascular Medicine: Rapid limb deterioration due to polyarteritis nodosa. ⁶²	Xu L...Hong S	36190788	2022
35	Clinical image: ultrasound findings and magnetic resonance imaging comparison in the muscular involvement in polyarteritis nodosa. ⁶²	Bixio R...Viapiana O	36471118	2022
36	Cutaneous polyarteritis nodosa diagnosis and treatment: A retrospective case series. ⁶²	Stewart M...Chan J	35714785	2022
37	Letter from the Editor: Management of cutaneous polyarteritis nodosa. ⁶²	Elston DM	35643240	2022
38	Predictive role of red blood cell distribution width to platelet ratio combined mean platelet volume in patients with microscopic polyangiitis. ⁶²	Jiang F...Zhu Y	36472404	2022
39	Correction to: Immunoglobulin G4-related coronary periarteritis: a systematic literature review with a case series. ⁶²	Ito T...Okada M	35951274	2022
40	A Novel Antineutrophil Extracellular Trap Antibody Targeting Myosin Light Chain 6 in Microscopic Polyangiitis. ⁶²	Yoshinari M...Ishizu A	35705243	2022
41	Hepatic artery pseudoaneurysms and hepatic ischaemic injury: a rare complication of polyarteritis nodosa. ⁶²	Bromfield B...Duarte-Rojo A	36450409	2022
42	Reporting complete heart block in a patient with polyarteritis nodosa after COVID-19 vaccination. ⁶²	Mehrabi Nasab E...Athari SS	36347818	2022
43	An adult case of suspected A20 haploinsufficiency mimicking polyarteritis nodosa. ⁶²	Niwano T...Yasuda S	35595232	2022
44	Coronary Artery Aneurysm Rupture in a Patient With Polyarteritis Nodosa. ⁶²	Schafigh M...Silaschi M	36444190	2022
45	The spectrum of cutaneous polyarteritis nodosa. A case report of two contrasting cases and review of the literature. ⁶²	Liang I...Manolios N	36447655	2022
46	Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review. ⁶²	Berti A...Ramiro S	35293985	2022
47	A Report of 2 Cases of Kidney Involvement in ADA2 Deficiency: Different Disease Phenotypes and the Tissue Response to Type I Interferon. ⁶²	Trivioli G...Vaglio A	35817275	2022
48	Intravenous immunoglobulin for chronic residual peripheral neuropathy in microscopic polyangiitis: A multicentre randomised double-blind trial. ⁶²	Arimura Y...Makino H	36346309	2022
49	Association between Serum Biomarkers and Peripheral Neuropathy in Microscopic Polyangiitis. ⁶²	Masuda Y...Takeuchi T	36362162	2022
50	Coexistence of relapsing polychondritis and eosinophilic granulomatous with polyangiitis: A rare entity. ⁶²	Ozgur DS...Bes C	36373442	2022

Sources

Genes for Polyarteritis Nodosa

Genes related to Polyarteritis Nodosa (0 elite genes):

(show all 23)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	ADA2	Adenosine Deaminase 2	Protein Coding	42.93	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	PRTN3	Proteinase 3	Protein Coding	24.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7754755 7907475
3	MEFV	MEFV Innate Immunity Regulator, Pyrin	Protein Coding	22.4	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18035151 10709887 19796529
4	IFNA2	Interferon Alpha 2	Protein Coding	17.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7912504
5	CRP	C-Reactive Protein	Protein Coding	15.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	MPO	Myeloperoxidase	Protein Coding	14.17	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11149660 7933581 9146079 (more) 1464072 1466365
7	IL6	Interleukin 6	Protein Coding	13.98	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	13.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	12.96	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	APOH	Apolipoprotein H	Protein Coding	12.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	SELE	Selectin E	Protein Coding	12.49	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	12.34	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	VCAM1	Vascular Cell Adhesion Molecule 1	Protein Coding	12.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	SELP	Selectin P	Protein Coding	11.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	MSN	Moesin	Protein Coding	11.56	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	11.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	SELL	Selectin L	Protein Coding	11.38	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	ITGB2	Integrin Subunit Beta 2	Protein Coding	10.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	ITGAL	Integrin Subunit Alpha L	Protein Coding	10.71	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	ICAM2	Intercellular Adhesion Molecule 2	Protein Coding	7.93	GeneCards inferred via : Publications (show sections)
21	ICAM3	Intercellular Adhesion Molecule 3	Protein Coding	7.93	GeneCards inferred via : Publications (show sections)
22	ITGA4	Integrin Subunit Alpha 4	Protein Coding	7.93	GeneCards inferred via : Publications (show sections)
23	TNF	Tumor Necrosis Factor	Protein Coding	6.4	DISEASES inferred ¹⁴

Sources

Variations for Polyarteritis Nodosa

ClinVar genetic disease variations for Polyarteritis Nodosa:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ADA2	NM_001282225.2(ADA2):c.-46-108_542+142del	DEL	Likely Pathogenic	973523		GRCh37: 22:17687819-17690721 GRCh38: 22:17206929-17209831

Sources

Expression for Polyarteritis Nodosa

Search GEO for disease gene expression data for Polyarteritis Nodosa.

Sources

Pathways for Polyarteritis Nodosa

Pathways related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

(show all 29)

#	Super pathways	Score	Top Affiliating Genes
1	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.33	VCAM1 PECAM1 MSN ITGB2 ITGAL ICAM2
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.25	VCAM1 PRTN3 MSN ITGB2 IL6 IFNA2
3	Response to elevated platelet cytosolic Ca2+ ⁶⁶ Show member pathways Disinhibition of SNARE formation ⁶⁶ Hemostasis ⁶⁶ Platelet activation, signaling and aggregation ⁶⁶ Platelet degranulation ⁶⁶	13.19	SELP SELL SELE PRTN3 PECAM1 ITGB2
4	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.08	VCAM1 SELL PRTN3 PECAM1 MSN MPO
5	Extracellular matrix organization ⁶⁶ Show member pathways Degradation of the extracellular matrix ⁶⁶	12.67	VCAM1 PECAM1 ITGB2 ITGAL ICAM2 ICAM1
6	NF-kappaB Signaling ³	12.52	VCAM1 PECAM1 MPO ITGB2 ICAM2
7	Complement cascade ⁶⁶ Show member pathways Activation of C3 and C5 ⁶⁶ Classical Complement Pathway ⁶⁴ Complement Pathway ⁶⁴ Complement system ⁷⁴ Complement system in neuronal development and plasticity ⁷⁴ Lectin Induced Complement Pathway ⁶⁴ Regulation of Complement cascade ⁶⁶	12.5	SELP SELL SELE ITGB2 ICAM2 ICAM1
8	Blood-Brain Barrier and Immune Cell Transmigration: VCAM-1/CD106 Signaling ⁶⁵ Show member pathways Blood-Brain Barrier and Immune Cell Transmigration: CCL2/MCP-1 Signaling ⁶⁵ Blood-Brain Barrier and Immune Cell Transmigration: ICAM-1/CD54 Signaling ⁶⁵ Blood-Brain Barrier and Immune Cell Transmigration: VEGF Signaling ⁶⁵	12.41	VCAM1 MSN ITGB2 ITGAL ICAM1
9	Cell surface interactions at the vascular wall ⁶⁶ Show member pathways Fibronectin matrix formation ⁶⁶ PECAM1 interactions ⁶⁶ Tie2 Signaling ⁶⁶	12.08	SELP SELL SELE PECAM1 ITGB2 ITGAL
10	ECM proteoglycans ⁶⁶ Show member pathways Integrin cell surface interactions ⁶⁶ MED and pseudoachondroplasia genes ⁷⁴	12.02	ICAM1 ICAM2 ITGAL ITGB2 PECAM1 VCAM1
11	Adhesion ³	11.98	ICAM1 ICAM2 ITGB2 VCAM1
12	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.92	SELL MPO ITGAL IL6 IFNA2
13	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.91	VCAM1 ITGB2 IL6 ICAM1
14	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell ⁶⁶	11.86	VCAM1 SELL ITGB2 ITGAL ICAM2 ICAM1
15	CCL18 signaling pathway ⁷⁴	11.84	VCAM1 ITGB2 ITGAL IL6
16	Burn wound healing ⁷⁴	11.71	PECAM1 IL6 IFNA2 ICAM1
17	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.7	IL6 HLA-DRB1 CRP
18	Glucocorticoid receptor regulatory network ⁶¹	11.7	SELE IL6 ICAM1
19	Acute viral myocarditis ⁷⁴	11.68	ITGB2 ITGAL IL6
20	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.67	SELL IL6 IFNA2
21	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.66	CRP IL6 ITGB2 SELL
22	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.6	VCAM1 SELE IL6 ICAM1
23	miRNAs involvement in the immune response in sepsis ⁷⁴	11.59	VCAM1 IL6 ICAM1
24	Netrin-UNC5B signaling pathway ⁷⁴	11.5	VCAM1 SELE ICAM1
25	Thromboxane A2 receptor signaling ⁶¹	11.31	VCAM1 SELE ICAM1
26	amb2 Integrin signaling ⁶¹	11.2	SELP ITGB2 IL6 ICAM1
27	Immune response_Role of integrins in NK cells cytotoxicity ²²	11.2	VCAM1 ITGB2 ITGAL ICAM2 ICAM1
28	LDL Oxidation in Atherogenesis ⁶⁴	10.9	VCAM1 MPO ICAM1
29	Beta2 integrin cell surface interactions ⁶¹	10.82	VCAM1 ITGB2 ITGAL ICAM2 ICAM1

Sources

GO Terms for Polyarteritis Nodosa

Cellular components related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular exosome	GO:0070062	10.45	VCAM1 PRTN3 PECAM1 MSN MPO ITGB2
2	plasma membrane	GO:0005886	10.23	HLA-DRB1 ICAM1 ICAM2 PECAM1 SELE SELL
3	plasma membrane	GO:0005887	10.23	HLA-DRB1 ICAM1 ICAM2 PECAM1 SELE SELL
4	cell surface	GO:0009986	10.17	APOH HLA-DRB1 ICAM1 ITGAL ITGB2 MSN
5	membrane raft	GO:0045121	9.97	SELE PRTN3 PECAM1 ITGB2 ICAM1
6	external side of plasma membrane	GO:0009897	9.8	VCAM1 SELP SELE ITGB2 ITGAL ICAM1
7	extracellular space	GO:0005615	9.78	ADA2 APOH CRP GPT HLA-DRB1 ICAM1
8	integrin alphaL-beta2 complex	GO:0034687	9.56	ITGB2 ITGAL

Biological processes related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	inflammatory response	GO:0006954	10.27	CRP IFNA2 IL6 ITGAL ITGB2 MEFV
2	cell adhesion	GO:0007155	10.22	VCAM1 SELP SELL SELE PECAM1 ITGB2
3	response to lipopolysaccharide	GO:0032496	10.14	VCAM1 SELP SELE MPO
4	cell-cell adhesion	GO:0098609	10.13	VCAM1 PECAM1 ITGB2 ITGAL ICAM2 ICAM1
5	phagocytosis	GO:0006909	10	ITGAL ITGB2 PECAM1 PRTN3
6	cell adhesion mediated by integrin	GO:0033627	9.99	ITGB2 ITGAL ICAM1
7	establishment of endothelial barrier	GO:0061028	9.95	PECAM1 MSN ICAM1
8	membrane to membrane docking	GO:0022614	9.88	VCAM1 MSN ICAM1
9	leukocyte tethering or rolling	GO:0050901	9.86	VCAM1 SELP SELL SELE
10	heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules	GO:0007157	9.85	ICAM1 ITGAL SELE SELP VCAM1
11	neutrophil extravasation	GO:0072672	9.83	PRTN3 PECAM1
12	T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell	GO:0002291	9.8	ITGAL ICAM1
13	leukocyte cell-cell adhesion	GO:0007159	9.58	VCAM1 SELP SELL SELE PECAM1 MSN
14	leukocyte migration	GO:0050900	9.5	SELP SELL SELE MSN ICAM1

Molecular functions related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heparin binding	GO:0008201	9.96	SELP SELL MPO APOH ADA2
2	cell adhesion molecule binding	GO:0050839	9.76	ITGAL ITGB2 MSN VCAM1
3	glycosphingolipid binding	GO:0043208	9.67	SELP SELL
4	integrin binding	GO:0005178	9.65	VCAM1 ITGB2 ITGAL ICAM2 ICAM1
5	ICAM-3 receptor activity	GO:0030369	9.62	ITGB2 ITGAL
6	oligosaccharide binding	GO:0070492	9.1	SELP SELL SELE